Skip to main content
Study shows positive results for Medtronic's Resolute Onyx stent

A 101-patient, multicenter study presented at the annual EuroPCR conference showed that use of Medtronic's 2-mm zotarolimus-eluting stent, Resolute Onyx, for patients with coronary artery disease in extra-small vessels met its primary endpoint at 12 months. Use of the stent demonstrated high rates of lesion, device and procedure success, as well as a 5% rate of major adverse cardiac events, zero stent thrombosis and zero cardiac deaths.

Full Story: